Latest Boehringer Ingelheim Stories
Spanish-Language Resources Encourage Holding On to the Gift of Health RIDGEFIELD, Conn., Feb. 10, 2015 /PRNewswire/ -- Today, Boehringer Ingelheim Pharmaceuticals, Inc.
Only prescription medication in U.S. to combine the dual mechanisms of action of SGLT2 and DPP-4 inhibitors to improve glycemic control as an adjunct to diet and exercise RIDGEFIELD, Conn.
Redesigned Bi-vetmedica.com Features Mobile-ready Options, Online Research and Catalog of Scientific Publications by Knowledge Leaders ST. JOSEPH, Mo., Feb.
DiabetesSisters has received joint funding from Boehringer-Ingelheim and Eli Lilly in the amount of $50,0000 to support the creation of DiabetesSisters’ first Educational Library.
New choice between mist and dry powder inhalers for tiotropium RIDGEFIELD, Conn., Jan. 21, 2015 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc.
OXFORD, England, January 14, 2015 /PRNewswire/ -- Oxford BioTherapeutics announces today that Boehringer Ingelheim has exercised an option to receive exclusive rights to
HEIDELBERG, Germany, January 5, 2015 /PRNewswire/ -- BioMed X announced today that they have entered into a collaboration agreement with Boehringer Ingelheim to establish
- Phase I study results presented at American Society of Hematology Annual Meeting RIDGEFIELD, Conn., Dec. 8, 2014 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc.
- Large; stout; burly.